Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram (EEG) effect was combined with intracerebral glutamate determinations using microdialysis for rats receiving norfloxacin intravenously (150 mg/kg of body weight). The EEG effect (accompanied by tremors and seizures) was consistently observed without glutamate level modifications. Therefore, norfloxacin-inducted seizures are not triggered by intracerebral glutamate level enhancement.
Fluoroquinolone antibiotics may induce central nervous system excitatory side effects, including anxiety, nervousness, hallucination, and even seizures on rare occasions (3, 13) . It is usually asserted that these excitatory side effects result from inhibition of GABA (␥-aminobutyric acid) binding to its receptors (1, 11) . Using intracerebral microdialysis, however, Smolders et al. have previously observed in conscious rats norfloxacin-induced convulsions accompanied not by any apparent effect on the extracellular hippocampal GABA levels but rather by enhanced intracerebral glutamate concentrations (10) . Studies of the relationship between glutamate concentrations and epileptic seizures have yielded conflicting observations, as recently reviewed (12) . Smolders et al. have hypothesized that enhanced glutamate levels might be essential for the induction of norfloxacin seizures (10) , but it could also be argued that the generation, spreading, and maintenance of seizures eventually leads to glutamate release and elevation (9) . Quantitative electroencephalogram (EEG) recording combined with intracerebral microdialysis offers a unique opportunity to address this question. In rats treated with imipenem (5) and norfloxacin (2), increases in the total power of the EEG signal are related to behavioral modifications and the occurrence of tremor and partial seizures and can therefore be considered an appropriate surrogate pharmacodynamic (PD) end point for the investigation of the convulsant activity of these antibiotics in rats. Furthermore, the kinetics of this effect can be very precisely evaluated using pharmacokinetic (PK)-PD modeling techniques (2, 5) .
The objective of this study was therefore to combine quantitative EEG recording (for the characterization of seizure induction and maintenance) with intracerebral microdialysis using the hippocampus (for the measurement of glutamate levels) of rats (after the administration of norfloxacin) to look for a causality relationship between the two factors. The experiment was conducted in accordance with the Principles of Laboratory Animal Care (National Institutes of Health), and ethical approval was obtained from the Animal Ethics Committee of the Faculty of Pharmacy (BHE 2001/12/ AE). Norfloxacin was obtained from Sigma (Saint-Quentin Fallavier, France), and a salt was prepared as previously described (4). L-glutamate standards were supplied by Sigma. All chemicals used were of analytical grade, and the analytical solvents used were of high-performance liquid chromatography grade. Six male Sprague-Dawley rats (weighing 299 Ϯ 15 g) from Depres Breeding Laboratories (St. Doulchard, France) were used and handled as previously described (2). At 5 days before drug administration, a microdialysis CMA/12 guide cannula was implanted into the left dorsal hippocampus for glutamate determinations (7) and cortical electrodes were implanted for EEG recording (2) . The animals were placed in a thermostatted chamber (27°C) and were allowed to recover for 4 days before implantation of femoral catheters for drug administration and blood sampling was performed (2) . On the day of the experiment, rats were maintained in a plastic bowl, the guide canula obturator was replaced by a CMA/12 microdialysis probe (Phymep, Paris, France) (0.5 mm in diameter by 3 mm long), and immediately thereafter the miniature plug was connected to a moving connector to record and analyze the EEG signal as previously described (2) . The microdialysis probe was infused with a Ringer solution (6) at a flow rate of 2 l ⅐ min Ϫ1 for 1 h to stabilize the system. Then, two blank microdialysate samples were taken in preweighed vials at 15-min intervals. Norfloxacin was then injected as an intravenous bolus at a dose of 150 mg ⅐ kg Ϫ1 (422 M ⅐ kg Ϫ1 ) between 10:30 and 11:00 a.m. Blood samples were drawn for norfloxacin high-performance liquid chromatography determinations in plasma (2) . Dialysates were collected every 15 min for glutamate determinations (8) . PK-PD modeling was conducted as previously described (2) . A two-compartment open model was used to characterize the plasma drug concentration versus time profiles. PK parameters were then fixed, and a nonlinear leastsquares program (WinNonlin version 1.1; SCI Software, Carry, N.C.) was used to regress the PD model to the EEG data for each individual rat. An effect compartment model was applied for analysis of the PK-PD relationship, leading to an estimate of the rate constant for the elimination of the drug from the effect compartment k e0 . The profile of the EEG effect was described using a spline function derived from the Hill equation:
In this equation, P represents the total power (EEG effect) corresponding to the drug concentration in the effect compartment (C e ), P 0 represents the baseline effect value, B n represents the combined E max -(50% effective concentration) n parameters, and n represents a factor determining the steepness of the curve. The goodness of fit of each model was assessed by visual inspection and analysis of the residuals and of the percentage of the coefficient of variation associated to parameter estimates (2, 5) . Two control animals underwent the same experimental protocol except that norfloxacin administration was replaced by isotonic saline administration.
All rats exhibited mild-to-severe nonlethal seizures accompanied by a marked effect on the EEG signal. A PK-PD model (with an effect compartment linked to a two-open compartment model and a spline function to characterize the relationship between effect and concentration at the effect site) was successfully fitted to the data. Corresponding parameter estimates (Table 1) were consistent with previously reported values. Extracellular glutamate concentrations in the hippocampus had a tendency to fluctuate with time but no general trend could be observed, and similar fluctuations were observed in the two control rats. This observation may seem to be inconsistent with the previous report of enhancement of glutamate concentrations occurring with seizures (10) . However, the present study was conducted with Sprague-Dawley rats receiving norfloxacin at 150 mg/kg of body weight compared to Wistar rats treated with 300 mg/kg of norfloxacin in the previous experiment (10) , which could partially explain this apparent discrepancy. The difficulty of finding doses appropriate for the inducement of reversible and therefore nonlethal seizures but sufficiently severe to have an effect on the EEG signal was previously mentioned (2, 5) . Preliminary tests suggested that a 300 mg/kg dose of norfloxacin was too high for the present study, and the 150 mg/kg dose was considered a better compromise. In such circumstances, significant alteration of the EEG signal and seizure induction characteristics were consistently observed; these effects did not require any previous observable alteration of hippocampal glutamate levels, as illustrated in Fig. 1 . It can therefore be concluded that as previously suggested (10), enhancement of glutamate levels is not essential for the induction of seizures by norfloxacin treatment. The alternative hypothesis, stating that glutamate release and elevation are, rather, a consequence of norfloxacin-induced seizures, should now be preferred. Yet no glutamate alteration was observed in the present study, even after the clinical symptoms appeared. A possible explanation is that the intensity of the seizures that followed the administration of the 150 mg/kg dose might not have been sufficient to induce an enhancement of intracerebral glutamate levels.
In conclusion, this study has demonstrated (for the first time to our knowledge) the benefit of combining intracerebral mi- a Parameter definitions: AUC, area under the curve; CL, clearance; V ss , volume of distribution at steady state; t 1/2␤ , half-life at ␤ phase; k e0 , elimination rate constant; P 0 , EEG effect (total power); B n , combined E max -(50% effective concentration) n parameters; n, factor determining the steepness of the curves.
crodialysis for neuromediator determinations and quantitative EEG recording with PK-PD modeling to assess causality relationships between these various parameters.
